IBDEI2FZ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41418,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,41418,1,4,0)
 ;;=4^Z85.46
 ;;^UTILITY(U,$J,358.3,41418,2)
 ;;=^5063423
 ;;^UTILITY(U,$J,358.3,41419,0)
 ;;=Z85.47^^159^2005^100
 ;;^UTILITY(U,$J,358.3,41419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41419,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,41419,1,4,0)
 ;;=4^Z85.47
 ;;^UTILITY(U,$J,358.3,41419,2)
 ;;=^5063424
 ;;^UTILITY(U,$J,358.3,41420,0)
 ;;=Z85.51^^159^2005^84
 ;;^UTILITY(U,$J,358.3,41420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41420,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,41420,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,41420,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,41421,0)
 ;;=Z85.528^^159^2005^89
 ;;^UTILITY(U,$J,358.3,41421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41421,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,41421,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,41421,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,41422,0)
 ;;=Z85.6^^159^2005^80
 ;;^UTILITY(U,$J,358.3,41422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41422,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,41422,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,41422,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,41423,0)
 ;;=Z85.72^^159^2005^104
 ;;^UTILITY(U,$J,358.3,41423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41423,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,41423,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,41423,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,41424,0)
 ;;=Z85.79^^159^2005^94
 ;;^UTILITY(U,$J,358.3,41424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41424,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,41424,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,41424,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,41425,0)
 ;;=Z85.820^^159^2005^83
 ;;^UTILITY(U,$J,358.3,41425,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41425,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,41425,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,41425,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,41426,0)
 ;;=Z85.828^^159^2005^98
 ;;^UTILITY(U,$J,358.3,41426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41426,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,41426,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,41426,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,41427,0)
 ;;=Z85.71^^159^2005^78
 ;;^UTILITY(U,$J,358.3,41427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41427,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,41427,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,41427,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,41428,0)
 ;;=Z65.8^^159^2005^138
 ;;^UTILITY(U,$J,358.3,41428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41428,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,41428,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,41428,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,41429,0)
 ;;=Z86.11^^159^2005^115
 ;;^UTILITY(U,$J,358.3,41429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41429,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,41429,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,41429,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,41430,0)
 ;;=Z86.13^^159^2005^82
 ;;^UTILITY(U,$J,358.3,41430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41430,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,41430,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,41430,2)
 ;;=^5063463
